Detailed price information for Broadridge Financial Solutions Llc (BR-N) from The Globe and Mail including charting and trades.

Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

This package summarizes data from the Brokerage, Dealers' and Bank reports, looking at trends across the financial advice ...

DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the third quarter ended September 30, 2025, along with ...

Also included in cash used in operations for the third quarter of 2025 is inventory financing payments of $1,378,000 for golf cart purchases of Venom under our financing agreement, which is expected ...